Velano’s needle-free technology enables high-quality blood draws from existing peripheral intravenous catheter (PIVC) lines. With this BD can now enable health care providers to help eliminate multiple needlesticks for blood sample collection, reducing the pain and discomfort from the process while delivering quality outcomes and increased patient satisfaction.
“As a global leader in vascular access solutions and blood collection, BD has been on the forefront of innovations that improve the patient experience and reduce additional needlesticks,” said Rick Byrd, president of Medication Delivery Solutions for BD. “Now, with the addition of Velano and its groundbreaking technologies, we can envision a world where a ‘One-Stick Hospital Stay’ could be a reality for many by making the numerous inpatient blood draws better for everyone.”
The acquisition closely follows BD spinning off its diabetes unit into a publicly-traded company. The diabetes unit generated revenues of nearly $1.1 billion with 48% of revenues generated outside of the U.S., including 17% of revenues from emerging markets. BD said the new company will have manufacturing sites in the United States, Ireland, and China, and is expected to have office locations in New Jersey and Massachusetts.
